The team at POPS! Diabetes Care, Inc. has plenty of reason to celebrate this summer. They recently closed an oversubscribed Series A funding of $6 Million, with incredible investor demand. Their product, a digital system which allows users to track and manage their A1C and insulin levels through an app and connected monitoring device, is making major waves in the healthcare space. FDA approval was reached in November of 2018, and in preliminary clinical research, their product demonstrated a 1-point drop in overall A1C for users.